Single-Dose And Multiple-Dose Safety And Tolerability Study Of PF-04856883 In Type 2 Diabetic Adult Females
NCT01301456 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 84
Last updated 2018-02-09
Summary
The primary objective of this study is to evaluate the safety and tolerability of PF-04856883 (CVX-096) in adult female subjects with Type 2 diabetes mellitus on high dose of metformin.
Conditions
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Glucose Metabolism Disorders
- Metabolic Diseases
- Endocrine System Diseases
Interventions
- BIOLOGICAL
-
Single subcutaneous injection of placebo
- BIOLOGICAL
-
PF-04856883
Single subcutaneous injection of PF-04856883
- BIOLOGICAL
-
PF-04856883
Single subcutaneous injection of PF-04856883
- BIOLOGICAL
-
PF-04856883
Single subcutaneous injection of PF-04856883
- BIOLOGICAL
-
Single subcutaneous injection of placebo
- BIOLOGICAL
-
PF-04856883
Single subcutaneous injection of PF-04856883
- BIOLOGICAL
-
PF-04856883
Single subcutaneous injection of PF-04856883
- BIOLOGICAL
-
PF-04856883
Single subcutaneous injection of PF-04856883
- BIOLOGICAL
-
Multiple weekly subcutaneous injections of placebo for 3 weeks
- BIOLOGICAL
-
PF-04856883
Multiple weekly subcutaneous injections of PF-04856883 for 3 weeks
- BIOLOGICAL
-
PF-04856883
Multiple weekly subcutaneous injections of PF-04856883 for 3 weeks
- BIOLOGICAL
-
PF-04856883
Multiple weekly subcutaneous injections of PF-04856883 for 3 weeks
- BIOLOGICAL
-
PF-04856883
Multiple weekly subcutaneous injections of PF-04856883 for 3 weeks
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Pfizer CT.gov Call Center · Pfizer
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 70 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2011-03-31
- Primary Completion
- 2011-12-31
- Completion
- 2012-04-30
Countries
- United States
Study Locations
More Related Trials
-
Multiple Dose Study Of PF-04937319 In Patients With Type 2 Diabetes
NCT01272804 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06882961 in Japanese Adults With Type 2 Diabetes Mellitus
NCT04552470 ·Status: COMPLETED ·Phase: PHASE1
-
Safety And Tolerability Of Escalating Intravenous Doses Of PF-05231023 In Adult Subjects With Type 2 Diabetes
NCT01285518 ·Status: COMPLETED ·Phase: PHASE1
-
A Study Of PF-05190457 In Healthy Volunteers And Type-2 Diabetic Patients
NCT01372163 ·Status: TERMINATED ·Phase: PHASE1
-
A Study of the Safety, Pharmacokinetics, and Pharmacodynamics of CNTO 3649 in Healthy Adults and Patients With Type 2 Diabetes Mellitus
NCT00882726 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of PF-05175157 in Healthy Volunteers and Type 2 Diabetic Patients
NCT01396161 ·Status: COMPLETED ·Phase: PHASE1
-
A Multiple Dose Study Of PF-04620110 In Type 2 Diabetes Patients
NCT01298518 ·Status: COMPLETED ·Phase: PHASE1
-
A Trial Investigating the Effect of 4 Weeks Dosing of XEN-D0501 on Blood Glucose Reduction in Patients With Diabetes
NCT05353686 ·Status: COMPLETED ·Phase: PHASE2
-
A 6-Week Study To Determine The Safety And Effect Of An Investigational Drug On Adults With Type 2 Diabetes Mellitus Taking Metformin
NCT02053103 ·Status: TERMINATED ·Phase: PHASE2
-
A Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Type 2 Diabetes Mellitus
NCT01028963 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Multiple Oral Doses of PF-07081532 in Adult Participants With Type 2 Diabetes Mellitus
NCT05158244 ·Status: COMPLETED ·Phase: PHASE1
-
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8655 in Participants With Type 2 Diabetes (MK-8655-002)
NCT01640873 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of PF-06882961 in Chinese Adults With Type 2 Diabetes Mellitus
NCT04889157 ·Status: COMPLETED ·Phase: PHASE1
-
A 6-Week Study Of PF-05175157 In Type 2 Diabetes Mellitus
NCT01792635 ·Status: TERMINATED ·Phase: PHASE2
-
Single Doses of MK-0941 in Type 2 Diabetics (MK-0941-027)
NCT01106287 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Assess the Safety, Tolerability, PK and PD Response of PE0139 Injection in Adult Subjects With T2DM
NCT02581657 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy of PB-119 in Subjects With Type 2 Diabetes and Not Well-controlled by Metformin Monotherapy
NCT04504396 ·Status: COMPLETED ·Phase: PHASE3
-
Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06291874 As Oral Monotherapy To Treat Adults With Type 2 Diabetes Mellitus
NCT02175121 ·Status: COMPLETED ·Phase: PHASE2
-
Multiple Dose Study of PF-04991532 in Patients With Type 2 Diabetes
NCT01129258 ·Status: COMPLETED ·Phase: PHASE1
-
Safety Study of BMS-903452 in Healthy Subjects (Panel 1-7) & Relative Bioavailability of the Crystalline and Amorphous Forms of BMS-903452 [Panels 4, 6, 11 & 12(Part A)], and Subjects With Type 2 Diabetes Mellitus (Part B)
NCT01240980 ·Status: COMPLETED ·Phase: PHASE1
-
A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of JNJ-28431754 in Patients With Type 2 Diabetes Mellitus
NCT00963768 ·Status: COMPLETED ·Phase: PHASE1
-
Randomized, Placebo-controlled, 2 Period, Single-blind, Sequential, Multiple Ascending Dose Study
NCT01956305 ·Status: COMPLETED ·Phase: PHASE1
-
Phase 1 Multicenter, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Response of PE0139 Injection in Adult Subjects With Type 2 Diabetes Mellitus
NCT01835730 ·Status: COMPLETED ·Phase: PHASE1
-
A Single Dose Study In Japanese And Western Healthy Subjects To Investigate The Safety, Tolerability And Pharmacokinetics Of PF-04991532
NCT01369277 ·Status: COMPLETED ·Phase: PHASE1
-
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 44847 in Female and Male Patients With Type 2 Diabetes
NCT02211963 ·Status: COMPLETED ·Phase: PHASE1